Ozempic is a well-known name, primarily approved for diabetes treatment in the UK and US, yet it is commonly prescribed ‘off-label’ for weight loss. This medication has essentially become synonymous with a groundbreaking new category of weight loss drugs.

Injectable medications like Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Saxenda can facilitate significant weight loss, approaching 20% of a person’s body weight in certain individuals.

Now, the next generation of weight loss solutions has arrived, and they are available in pill form.

The debut of these tablets occurred in the United States, with Novo Nordisk (the producer of Ozempic) launching Wegovy tablets on January 5, 2026. Their quick rise in popularity resulted in over 18,000 new prescriptions issued in the first week alone.

But Wegovy won’t stand alone for long. Eli Lilly’s competing drug, orforglipron, is projected to gain FDA approval this spring, and several alternatives are in development.

(Currently, these tablets are not available in the UK; however, UK policies are anticipated to follow the FDA’s example.)

The mechanism of these tablets mirrors that of injectables. The active compounds, known as “incretins” (like Wegovy’s semaglutide and Mounjaro’s tirzepatide), deceive the body into feeling full by imitating natural satiety hormones.

As digestion slows down, you naturally consume less, leading to weight loss. Don’t let hunger hinder your journey to success.

Now available in pill form, this medication promises similar life-altering effects and protection against obesity-related illnesses, all while being more affordable than ever.

Is it too good to be true? Experts caution that while the pill presents notable risks, it also brings substantial benefits.

Read more:

Can Weight Loss Drugs Transform the Landscape of Treatment?

These tablets could signify a new chapter in the management of obesity, providing broader access to life-altering healthcare.

“Not everyone prefers injectable medications,” states Dr. Simon Cork, a senior lecturer in appetite and weight regulation at Anglia Ruskin University in the UK. “Injections can be uncomfortable for many patients, making oral administration a more appealing option.”

Besides comfort, switching from injections to pills could massively reduce monthly costs. Those using weight loss drugs today often spend hundreds of dollars each month on injections.

Thanks to the absence of needles and refrigeration needs, these pills can be produced and distributed at lower costs, providing weight loss solutions to millions who previously faced exorbitant prices.

“Overall, these pills are expected to be significantly more affordable than current injection therapies,” says Cork.

This trend is already visible in the US, where Wegovy pens are priced at $349 (approximately £250) per month, whereas Wegovy tablets retail for $149 (around £110).

In the UK, nearly 95% of incretin users incur high private fees. According to Professor Giles Yeo from the University of Cambridge, the NHS often cannot prescribe these expensive medications to all patients who need them.

“Patients may need to maintain these drugs for extended periods, which exacerbates the financial barrier, particularly for those from disadvantaged backgrounds most susceptible to obesity,” Cork noted. “I hope that these oral medications will democratize access.”

Addressing Long-Term Challenges

However, these drugs may not be the most effective options, even as their availability increases.

Incretins tend to offer lower efficacy in pill form. Injectable Wegovy has demonstrated a capacity to help users lose 15% of body weight after 68 weeks, while Wegovy tablets showed only 13.6% weight loss across 64 weeks.

The efficacy of pills may not match that of modern injected solutions. Retatortide, still in development, has shown results of 24% body weight reduction in just 48 weeks.

Administering these drugs through pills poses inherent challenges. Oral medications must traverse the stomach and liver before entering circulation, resulting in the manufacturer needing to increase the amount of active ingredient to achieve desired outcomes.

Consequently, weight loss results from pills may not be as rapid as from injections. Nevertheless, a significant complaint regarding injections—that discontinuing them often leads to weight regain—may see improvement.

A 2022 study revealed that participants who halted Wegovy injections regained up to two-thirds of their lost weight within one year.

The emergence of the pill could provide a solution. A recent study, the Eli Lilly ATTAIN-MAINTAIN Trial, showed that Orforglipron tablets helped participants stabilize their weight after stopping injectable therapy.

“Many might rely on these medications to maintain weight loss,” Yeo suggests.

Cork adds, “Injectables can be utilized for optimal weight loss, and pills can help maintain this weight affordably.”

The Risks and Concerns of the Pill Revolution

While these drugs possess the potential to catalyze significant positive change, their widespread availability also raises risks for vulnerable populations.

“The major danger is these drugs entering the wrong hands,” warns Yeo. “Since there’s no weight limit to how these drugs might impact individuals, a 300-pound person aiming to lose 50 pounds could utilize it as well as a 16-year-old girl weighing 75 pounds.”

“Pills can easily be trafficked, making them accessible to anyone. It’s essential to establish strict regulations around their distribution,” he urges.

Cork shares concerns over side effects. Incretins can provoke various symptoms, including nausea, vomiting, constipation, and diarrhea. Clinical trials found that three-quarters of participants experienced digestive issues.

Moreover, there are rare but serious risks such as pancreatitis, gallstones, and gastroparesis. Additionally, interactions with other medications, including contraceptives, could affect their efficacy.

“The risk of pancreatitis is low, around 1%,” Cork notes. “But with millions potentially using these drugs, this risk becomes concerning without appropriate oversight.”

Though these warnings are sobering, they remain speculative. The actual impact of these drugs is still uncertain.

“2026 is poised to be a crucial year in understanding the efficacy, prevalence, and applications of these medications,” Yeo concludes. “Time will tell how things unfold.”

Read more: